Cerity Partners LLC Decreases Stock Position in Haemonetics Co. (NYSE:HAE)

Cerity Partners LLC decreased its position in Haemonetics Co. (NYSE:HAE) by 5.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,345 shares of the medical instruments supplier’s stock after selling 510 shares during the quarter. Cerity Partners LLC’s holdings in Haemonetics were worth $671,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in HAE. Norges Bank acquired a new stake in Haemonetics during the 4th quarter valued at $32,803,000. Groupama Asset Managment acquired a new stake in shares of Haemonetics during the fourth quarter valued at about $19,520,000. Raymond James Financial Inc. purchased a new stake in shares of Haemonetics during the fourth quarter worth about $19,002,000. Thrivent Financial for Lutherans lifted its stake in shares of Haemonetics by 14.9% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier’s stock worth $98,716,000 after acquiring an additional 164,111 shares in the last quarter. Finally, Boston Partners boosted its holdings in Haemonetics by 27.5% in the fourth quarter. Boston Partners now owns 536,262 shares of the medical instruments supplier’s stock valued at $41,485,000 after purchasing an additional 115,506 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Up 0.4 %

HAE stock opened at $57.10 on Monday. The stock has a market cap of $2.87 billion, a PE ratio of 22.48, a price-to-earnings-growth ratio of 1.11 and a beta of 0.41. The firm’s 50-day simple moving average is $63.06 and its 200 day simple moving average is $72.68. Haemonetics Co. has a fifty-two week low of $55.30 and a fifty-two week high of $97.97. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, sell-side analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Bank of America lowered Haemonetics from a “neutral” rating to an “underperform” rating and cut their target price for the company from $95.00 to $68.00 in a research report on Friday, February 7th. Barrington Research decreased their price objective on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a report on Friday, February 7th. JMP Securities cut their target price on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research note on Friday, February 7th. Raymond James reiterated a “strong-buy” rating and issued a $115.00 price target (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Finally, Needham & Company LLC cut their price objective on Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a research note on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $101.22.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.